Context Therapeutics Inc. 8-K

What Happened
Context Therapeutics Inc. announced that on March 11, 2026 the Delaware Court of Chancery approved a stipulated judgment finding two charter provisions invalid (director three‑year terms and removal only for cause). The company filed a Certificate of Correction the same day. A Stipulated Order required payment of an $850,000 mootness fee to plaintiff’s counsel; under a April 30, 2026 letter agreement, a third‑party service provider agreed to pay that fee on the company’s behalf, and the provider paid the $850,000 in full on May 1, 2026. The underlying stockholder action was dismissed with prejudice as to the plaintiff; the case will be closed after the Court is informed a quorum was achieved at Context’s 2026 annual meeting scheduled for June 24, 2026.

Key Details

• Court approval and dismissal: Stipulated Judgment approved March 11, 2026; action dismissed with prejudice as to plaintiff.
• Charter edits: Article V, Section 2 (three‑year director terms) and Article VI, Section 1 (removal only for cause) were declared invalid and removed via Certificate of Correction on March 11, 2026.
• Mootness fee: Stipulated Order required $850,000 to plaintiff’s counsel; third‑party Provider agreed on April 30, 2026 and paid $850,000 on May 1, 2026.
• Case closure: Court retained jurisdiction over any mootness fee issues; case will be closed after confirmation of a quorum at the June 24, 2026 annual meeting.

Why It Matters
This filing affects corporate governance: two charter provisions concerning director terms and removal were declared invalid and removed, which could change how the board is structured and how directors may be replaced. The $850,000 fee was paid by a third‑party provider rather than directly by the company, so the filing indicates no immediate cash outlay by Context for that payment. Investors should note the legal risk was resolved through dismissal and payment, and the matter will be formally closed once the court receives confirmation of the annual meeting quorum.